Tweet
I am going to be tracking changes in methylation status of cells over time and with varying treatments. For MBD seq do I need to sequence a corresponding input reaction for every time point and treatment or can I compare the different groups to each other instead? I will be analyzing untreated time point one as a baseline. Would this suffice?
-
-
In general when we're doing this type of enrichment work we only do a single input sample using the same conditions as for the enriched samples. Most of the artefacts come from the DNA preparation, mapping and sequencing stages and won't change between timepoints or treatments (unless you have a treatment which is going to grossly change the structure of your DNA in some way). Doing a matched input for each sample would get really expensive really quickly!
In some cases we don't bother doing an input at all but just use data from previous inputs we've run to either use in the analysis or to provide sets of regions which we should ignore.
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment